WO2023152199A1 - Utilisation d'une composition de soin buccal comprenant du zinc - Google Patents

Utilisation d'une composition de soin buccal comprenant du zinc Download PDF

Info

Publication number
WO2023152199A1
WO2023152199A1 PCT/EP2023/053141 EP2023053141W WO2023152199A1 WO 2023152199 A1 WO2023152199 A1 WO 2023152199A1 EP 2023053141 W EP2023053141 W EP 2023053141W WO 2023152199 A1 WO2023152199 A1 WO 2023152199A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
zinc
oral care
care composition
zinc salt
Prior art date
Application number
PCT/EP2023/053141
Other languages
English (en)
Inventor
Suzanne Elizabeth ADAMS
Andrew Kenneth CAWLEY
Joanne Elizabeth HUNT
Vera SLOMKA
Original Assignee
Unilever Ip Holdings B.V.
Unilever Global Ip Limited
Conopco, Inc., D/B/A Unilever
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Ip Holdings B.V., Unilever Global Ip Limited, Conopco, Inc., D/B/A Unilever filed Critical Unilever Ip Holdings B.V.
Publication of WO2023152199A1 publication Critical patent/WO2023152199A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention relates to oral care compositions, in particular to oral care compositions comprising zinc salts.
  • Zinc salts have been used in some oral care compounds for a number of years.
  • US 5470561 discloses an anti-plaque mouthwash comprising a zinc salt and triclosan.
  • the composition may also comprise glycine and has a pH of between 4 and 8, preferably between 5 and 7, the preferred pH being 6.
  • Toothpaste compositions comprising zinc salts are disclosed in WO0612977.
  • the toothpaste comprises water, a zinc salt, a chelating agent for the zinc.
  • US 5632 972 discloses a method for minimising damage to gingival and periodontal tissue by delivering a first component comprising zinc and a second component comprising a bicarbonate.
  • Lysine is thought to be of importance for gum health and to play a role in gingival tissue attachment to enamel surfaces. During the shift towards unhealthy conditions, lysine is depleted by the bacterial enzyme lysine decarboxylase, impairing tissue attachment.
  • the present invention relates to an oral composition comprising a zinc salt for use in a method to strengthen gum adhesion within the mouth.
  • the invention further relates to the use of a zinc salt in the preparation of a composition to strengthen gum adhesion to the teeth.
  • any feature of one aspect of the present invention may be utilised in any other aspect of the invention.
  • Any feature described as ‘preferred’ should be understood to be particularly preferred in combination with a further preferred feature or features.
  • any feature of a particular embodiment may be utilized in any other embodiment of the invention.
  • the word ‘comprising’ is intended to mean ‘including’ but not necessarily ‘consisting of or ‘composed of. In other words, the listed steps or options need not be exhaustive.
  • All percentages are weightA/veight percentages unless otherwise indicated.
  • the present invention relates to oral compositions comprising a zinc salt for use in a method to strengthen gum adhesion within the mouth.
  • the genes associated with lysine biosynthesis comprise: aspartate kinase EC:2.7.2.4, aspartate-semialdehyde dehydrogenase EC: 1.2.1.11, dihydrodipicolinate reductase EC: 1.17.1.8, diaminopimelate decarboxylase EC:4.1.1.20, dihydrodipicolinate synthase EC:4.3.3.7, diaminopimelate epimerase EC:5.1.1.7, 2,3,4,5-tetrahydropyridine-2-carboxylate N-succinyltransferase EC:2.3.1.117, or mixtures thereof.
  • compositions according to the invention comprise a zinc salt, preferably they comprise a water- soluble or sparingly water-soluble sources of zinc ions such as zinc chloride, zinc acetate, zinc gluconate, zinc sulphate, zinc fluoride, zinc lactate, zinc oxide, zinc monoglycerolate, zinc tartrate, zinc pyrophosphate and zinc maleate.
  • Zinc citrate trihydrate is particularly preferred.
  • the zinc salt is preferably present at from 0.01 to 5% by weight of the total composition, more preferably 0.1 to 4 wt%, most preferably from 0.5 to 3.0wt%.
  • composition of the invention is preferably used to clean the surfaces of the oral cavity and is known as an oral care composition, the composition may be suitable for cosmetic and/or medical use.
  • compositions of the invention are those which are suitable for brushing and/or rinsing the surfaces of the oral cavity.
  • the composition of the invention is most preferably in the form of a dentifrice.
  • dentifrice denotes an oral composition which is used to clean the surfaces of the oral cavity. Such a composition is not intentionally swallowed for purposes of systemic administration of therapeutic agents, but is applied to the oral cavity, used to treat the oral cavity and then expectorated. Typically, such a composition is used in conjunction with a cleaning implement such as a toothbrush, usually by applying it to the bristles of the toothbrush and then brushing the accessible surfaces of the oral cavity.
  • a cleaning implement such as a toothbrush
  • the dentifrice/toothpaste is in the form of an extrudable semi-solid such as a cream, paste or gel (or mixture thereof).
  • a composition according to the invention (such as a dentifrice/toothpaste) will generally contain further ingredients to enhance performance and/or consumer acceptability, in addition to the ingredients specified above.
  • Compositions according to the invention preferably comprise particulate abrasive materials such as silicas, aluminas, calcium carbonates, dicalciumphosphates, calcium pyrophosphates, hydroxyapatites, trimetaphosphates, insoluble hexametaphosphates and so on, including agglomerated particulate abrasive materials, usually in amounts between 3 and 60% by weight of the oral care composition.
  • particulate abrasive materials such as silicas, aluminas, calcium carbonates, dicalciumphosphates, calcium pyrophosphates, hydroxyapatites, trimetaphosphates, insoluble hexametaphosphates and so on, including agglomerated particulate abrasive materials, usually in amounts between 3 and 60% by weight of the oral care composition.
  • the composition particularly a toothpaste, comprises a silica based abrasive.
  • the preferred abrasive silicas used in the present invention is a silica with a low refractive index. It may be used as the sole abrasive silica, or in conjunction with a low level of other abrasive silicas, e.g. those according to EP 236070.
  • suitable low refractive index abrasive silicas e.g. having an R.l.
  • silicas of between 1 .435 and 1 .445) are Tixosil 63 and 73 ex Rhone Poulenc; Sident 10 ex Degussa; Zeodent 113 ex Zeofinn; Zeodent 124 ex Huber, Sorbosil AC 77 ex Crosfield Chemicals (having an R.l. of approximately 1.440).
  • the amount of these silicas in the total composition generally ranges from 5-60% by weight, usually 5-20% by weight.
  • composition particularly if a toothpaste, preferably comprises an inorganic or a natural or synthetic thickener or gelling agent in proportions of about 0.10 to about 15% by weight depending on the material chosen.
  • thickeners in the dentifrice compositions of the present invention form an extrudable, shape-retaining product which can be squeezed from a tube onto a toothbrush and will not fall between the bristles of the brush but rather, will substantially maintain its shape thereon.
  • Suitable thickeners or gelling agents useful in the practice of the present invention include inorganic thickening silicas such as amorphous silicas available from Huber Corporation under the trade designation Zeodent 165, Irish moss, iota-carrageenan, gum tragacanth, and polyvinylpyrrolidone.
  • inorganic thickening silicas such as amorphous silicas available from Huber Corporation under the trade designation Zeodent 165, Irish moss, iota-carrageenan, gum tragacanth, and polyvinylpyrrolidone.
  • compositions according to the invention preferably comprise a polymeric deposition aid.
  • the composition comprises acid anhydride polymers, particularly preferred are co-polymers of maleic anhydride with methyl vinylether, in which the anhydride moiety may be in a partially or fully hydrolysed or alcoholysed form.
  • Preferred copolymers include Gantrez(R) polymers such as: Gantrez S-95: molecular weight 216,000; free acid;
  • Gantrez S-96 molecular weight 700,000; free acid
  • Gantrez S-97 molecular weight 1 ,500,000; free acid
  • Gantrez MS-955 molecular weight 1,060,000; calcium/sodium salt.
  • Particularly preferred co-polymers of maleic acid and methyl vinylether have a molecular weight of 1 ,000,000 or greater and an especially preferred material is Gantrez S-97.
  • compositions according to the invention may comprise a tooth whitening agent.
  • the whitening agent preferably comprises a green and/or a blue pigment.
  • a pigment is generally understood to be a shade/material which is insoluble in the relevant medium, at the relevant temperature. This is in contrast to dyes which are soluble.
  • the "relevant medium” is human saliva, the liquid medium in which the composition is used, at the temperature of the oral cavity during brushing of the teeth, i.e. up to 37 Degrees C. As a reasonable approximation, the relevant medium may be considered to be water and the relevant temperature to be 25 Degrees C.
  • the blue pigment is Pigment Blue 15, more preferably Pigment Blue 15:1 , 15:2, 15:3, 15:4, 15:5 or 15:6, most preferably 15:1.
  • a preferred pigment is blue pigment is Phthalocyanine Blue Pigment, Cl No. 74160, blue covarine.
  • the preferred green pigment is Phthalocyanine Green, preferably Phthalocyanine Green CI-74260.
  • the total level of pigment in the composition is from 0.01 wt% to 3 wt, more preferably from 0.02 to 2 wt%.
  • composition is a toothpaste it may be a dual phase paste, with the whitening pigments present in one phase.
  • compositions according to the invention may comprise oral care enzyme systems such as hydrogen peroxide producing enzyme systems (e.g. the oxidoreductase enzyme glucose oxidase), amyloglucosidase, dextranase and/or mutanase, (optionally in the presence of zinc ion providing compounds and/or 8- hydroxyquinoline derivatives), lactoperoxidase, lactoferrin, lysozyme and mixtures thereof.
  • Compositions of the invention may comprise fluoride sources such as sodium fluoride, stannous fluoride, sodium monofluorophosphate, zinc ammonium fluoride, tin ammonium fluoride, calcium fluoride, cobalt ammonium fluoride and mixtures thereof.
  • a preferred class of oral care active for inclusion in the compositions of the invention includes agents for the remineralisation of teeth.
  • remineralisation in the context of the present invention means the in situ generation of hydroxyapatite on teeth.
  • a specific example of a suitable agent for the remineralisation of teeth is a mixture of a calcium source and a phosphate source which, when delivered to the teeth results in the in situ generation of hydroxyapatite on teeth.
  • remineralising calcium sources include, for example, calcium phosphate, calcium gluconate, calcium oxide, calcium lactate, calcium glycerophosphate, calcium carbonate, calcium hydroxide, calcium sulphate, calcium carboxymethyl cellulose, calcium alginate, calcium salts of citric acid, calcium silicate and mixtures thereof.
  • the remineralising calcium source is calcium silicate.
  • the amount of remineralising calcium source(s) (e.g. calcium silicate) in the composition of the invention typically ranges from 1 to 30%, preferably from 5 to 20% by total weight remineralising calcium source based on the total weight of the oral care composition.
  • remineralising phosphate sources include, for example, monosodium dihydrogen phosphate, disodium hydrogen phosphate, sodium pyrophosphate, tetrasodium pyrophosphate, sodium tripolyphosphate, sodium hexametaphosphate, potassium dihydrogenphosphate, trisodium phosphate, tripotassium phosphate and mixtures thereof.
  • the remineralising phosphate source is a mixture of trisodium phosphate and sodium dihydrogen phosphate.
  • the amount of remineralising phosphate source(s) (e.g. trisodium phosphate and sodium dihydrogen phosphate) in the composition of this invention typically ranges from 2 to 15%, preferably from 4 to 10% by total weight remineralising phosphate source based on the total weight of the oral care composition.
  • composition according the invention will comprise further ingredients which are common in the art, such as: antimicrobial agents, e.g. chlorhexidine, sanguinarine extract, metronidazole, quaternary ammonium compounds, such as cetylpyridinium chloride; bis-guanides, such as chlorhexidine digluconate, hexetidine, octenidine, alexidine; and halogenated bisphenolic compounds, such as 2,2' methylenebis-(4-chloro-6-bromophenol); anti-inflammatory agents such as ibuprofen, flurbiprofen, aspirin, indomethacin etc.; anti-caries agents such as sodium- and stannous fluoride, aminefluorides, sodium monofluorophosphate, sodium trimeta phosphate and casein; plaque buffers such as urea, calcium lactate, calcium glycerophosphate and strontium polyacrylates; vitamins such as
  • Humectants such as glycerol, sorbitol, propyleneglycol, xylitol, lactitol etc.; binders and thickeners such as sodium carboxymethyl-cellulose, hydroxyethyl cellulose (Natrosol®), xanthan gum, gum arabic etc. as well as synthetic polymers such as polyacrylates and carboxyvinyl polymers such as Carbopol®; polymeric compounds which can enhance the delivery of active ingredients such as antimicrobial agents can also be included; buffers and salts to buffer the pH and ionic strength of the oral care composition; and other optional ingredients that may be included are e.g. bleaching agents such as peroxy compounds e.g. potassium peroxydiphosphate, effervescing systems such as sodium bicarbonate/citric acid systems, colour change systems, and so on.
  • bleaching agents such as peroxy compounds e.g. potassium peroxydiphosphate, effervescing systems such as sodium bicarbonate/c
  • RNA protect solution to stabilise the RNA prior to analysis of microbiome gene activity (metatranscriptomics).
  • RNA samples were pooled for each product and time point and spilt into three to provide replicates for RNA extraction and analysis, in total yielding 18 samples.
  • the RNA was extracted using the Qiagen AHPrep kit following the manufactures instructions and quantified using Qubit HS RNA kit again following the manufactures instructions.
  • the RNA samples were then subjected to RNA sequencing. Following depletion of the ribosomal RNA (rRNA) to allow sequencing of only the messenger RNA (mRNA) to focus on the more informative parts of the transcriptome, libraries were sequenced on an Illumina HiSeq 4000 platform.
  • rRNA ribosomal RNA
  • RNA sequence data was processed using a bioinformatics pipeline (Eagle Genomics) to determine microbiome community activity via analysis of gene expression (mRNA) using the HUMAnN2 database. Analysis of individual genes was conducted using JMP. Table 2

Abstract

L'invention concerne une composition de soin buccal comprenant un sel de zinc destinée à être utilisée dans un procédé pour l'amélioration de la biosynthèse de la lysine à l'intérieur de la bouche.
PCT/EP2023/053141 2022-02-09 2023-02-08 Utilisation d'une composition de soin buccal comprenant du zinc WO2023152199A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22155753 2022-02-09
EP22155753.1 2022-02-09

Publications (1)

Publication Number Publication Date
WO2023152199A1 true WO2023152199A1 (fr) 2023-08-17

Family

ID=80447770

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/053141 WO2023152199A1 (fr) 2022-02-09 2023-02-08 Utilisation d'une composition de soin buccal comprenant du zinc

Country Status (1)

Country Link
WO (1) WO2023152199A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0236070A2 (fr) 1986-02-28 1987-09-09 Unilever Plc Silices
US5470561A (en) 1991-12-11 1995-11-28 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Mouthwash compositions
WO1996004882A1 (fr) * 1994-08-10 1996-02-22 Block Drug Company Adhesif pour protheses dentaires
US5616313A (en) * 1994-06-30 1997-04-01 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Method for treating gingival and periodontal tissues
WO2006012977A1 (fr) 2004-08-03 2006-02-09 Unilever N.V. Composition
WO2014099164A2 (fr) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Complexe d'halogénure d'acide aminé de zinc avec de la cystéine
JP2016158665A (ja) * 2015-02-26 2016-09-05 小林製薬株式会社 義歯安定剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0236070A2 (fr) 1986-02-28 1987-09-09 Unilever Plc Silices
US5470561A (en) 1991-12-11 1995-11-28 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Mouthwash compositions
US5616313A (en) * 1994-06-30 1997-04-01 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Method for treating gingival and periodontal tissues
US5632972A (en) 1994-06-30 1997-05-27 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Method for treating gingival and periodontal tissues
WO1996004882A1 (fr) * 1994-08-10 1996-02-22 Block Drug Company Adhesif pour protheses dentaires
WO2006012977A1 (fr) 2004-08-03 2006-02-09 Unilever N.V. Composition
WO2014099164A2 (fr) * 2012-12-19 2014-06-26 Colgate-Palmolive Company Complexe d'halogénure d'acide aminé de zinc avec de la cystéine
JP2016158665A (ja) * 2015-02-26 2016-09-05 小林製薬株式会社 義歯安定剤

Similar Documents

Publication Publication Date Title
EP3979977B1 (fr) Composition de soins bucco-dentaires comprenant un sel de zinc pour utilisation comme médicament pour baisser la tension artérielle
US6475472B2 (en) Oral bleaching composition
JP2000154127A (ja) 口腔用組成物
EP4037640B1 (fr) Composition de spray de soin oral comprenant de l'hexametaphosphate
WO2023152199A1 (fr) Utilisation d'une composition de soin buccal comprenant du zinc
WO2023152198A1 (fr) Utilisation d'une composition pour soin buccal
EP4331563A1 (fr) Utilisation de composition de protection orale
EP4331561A1 (fr) Utilisation de composition de protection orale
EP4331562A1 (fr) Utilisation de composition de protection orale
RU2527343C1 (ru) Зубная паста, содержащая ферменты папаин, лактопероксидазу и лактулозу
EP3955883B1 (fr) Composition de soins personnels comprenant de la tétraméthylcurcumine et son procédé de production
EP3955884B1 (fr) Composition de soins personnels comprenant de la piperlongumine et son procédé de production
EP3952829B1 (fr) Procédé de préparation d'une composition de soins bucco-dentaires comprenant du gingerdiol
WO2023213460A1 (fr) Composition de soin buccodentaire
RU2801309C2 (ru) Композиция для ухода за полостью рта
EP4037641B1 (fr) Composition de soin oral comprenant de l' hexametaphosphate et un pigment
WO2023138996A1 (fr) Composition de soin buccodentaire
WO2023247290A1 (fr) Composition de soin buccodentaire pour atténuer et/ou inverser l'érosion de l'émail dentaire provoquée par l'usure d'un aligneur
WO2023138811A1 (fr) Composition de soin buccal
RU2535051C1 (ru) Зубная паста
WO2023227282A1 (fr) Composition de soin buccal
WO2023247291A1 (fr) Composition de soin buccodentaire pour atténuer et/ou inverser l'érosion de l'émail dentaire provoquée par le port d'un aligneur
WO2023186746A1 (fr) Composition de soin buccodentaire
WO2023247292A1 (fr) Composition de soin buccal atténuer et/ou réparer l'érosion de l'émail dentaire provoquée par le port d'un aligneur
WO2023186583A1 (fr) Composition de soin buccodentaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23703239

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)